- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Stopped Early
Phase
IIb
Objective
To continue evaluating the safety and begin evaluating the efficacy of an investigational HIV vaccine.
Prevention Option(s)
HIV Vaccine
Study Design
Controlled
Randomized
Double-blind
Arms and Assigned Interventions
Description
MRKAd5 HIV-1 gag/pol/nef trivalent vaccine
Mode of Delivery
Intramuscular
Products
Ad5
ARMs
Experimental
ARMs
Placebo Comparator
Trial Sponsors
NIAID, SAAVI
Product Developers
Merck
December 2004
September 2007
18
Years
45
Years
Population
Women
Men
Sites
Site(s) - United States
United States of America
Site(s) - Peru
Peru
Site(s) - Brazil
Brazil
STEP CRS
Santo Domingo
Dominican Republic
STEP CRS
Port-au-Prince
Haiti
STEP CRS
Kingston
Jamaica
STEP CRS
San Juan
Puerto Rico
STEP CRS
Sydney
Australia
Site(s) - Australia
Australia